- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.07 Å
- Oligo State
- homo-dimer
- Ligands
- 3 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 2 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 1 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 2 x PEG: DI(HYDROXYETHYL)ETHER(Non-functional Binders)
PEG.7: 8 residues within 4Å:- Chain A: L.244, S.245, W.246, Q.249
- Chain B: L.244, S.245, W.246, Q.249
6 PLIP interactions:3 interactions with chain B, 3 interactions with chain A- Hydrogen bonds: B:W.246, B:Q.249, A:W.246, A:Q.249
- Water bridges: B:N.241, A:L.244
PEG.8: 6 residues within 4Å:- Chain A: H.84, G.85, I.86, R.87, Q.88, W.131
3 PLIP interactions:3 interactions with chain A- Hydrogen bonds: A:H.84, A:I.86, A:Q.88
- 4 x ACT: ACETATE ION(Non-functional Binders)
ACT.9: 2 residues within 4Å:- Chain A: K.182, R.221
2 PLIP interactions:2 interactions with chain A- Salt bridges: A:K.182, A:R.221
ACT.10: 2 residues within 4Å:- Chain A: S.314, G.315
1 PLIP interactions:1 interactions with chain A- Hydrogen bonds: A:G.315
ACT.11: 6 residues within 4Å:- Chain A: F.198, A.199, D.200, I.201, S.207, S.210
1 PLIP interactions:1 interactions with chain A- Hydrogen bonds: A:S.210
ACT.25: 3 residues within 4Å:- Chain B: R.87, H.94, R.165
2 PLIP interactions:2 interactions with chain B- Salt bridges: B:H.94, B:R.165
- 6 x SO4: SULFATE ION(Non-functional Binders)
SO4.12: 5 residues within 4Å:- Chain A: R.301, I.336, A.337, S.340, R.371
4 PLIP interactions:4 interactions with chain A- Hydrogen bonds: A:A.337, A:S.340
- Salt bridges: A:R.301, A:R.371
SO4.13: 4 residues within 4Å:- Chain A: L.1, D.2, R.189, Q.190
3 PLIP interactions:3 interactions with chain A- Hydrogen bonds: A:D.2
- Water bridges: A:D.2
- Salt bridges: A:R.189
SO4.14: 2 residues within 4Å:- Chain A: H.94, R.165
2 PLIP interactions:2 interactions with chain A- Salt bridges: A:H.94, A:R.165
SO4.26: 5 residues within 4Å:- Chain B: R.301, I.336, A.337, S.340, R.371
4 PLIP interactions:4 interactions with chain B- Hydrogen bonds: B:A.337, B:S.340
- Salt bridges: B:R.301, B:R.371
SO4.27: 4 residues within 4Å:- Chain B: L.1, D.2, R.189, Q.190
5 PLIP interactions:5 interactions with chain B- Hydrogen bonds: B:L.1, B:D.2
- Water bridges: B:D.2, B:R.7
- Salt bridges: B:R.189
SO4.28: 4 residues within 4Å:- Chain B: Q.299, L.300, R.301, Q.302
1 PLIP interactions:1 interactions with chain B- Hydrogen bonds: B:Q.302
- 2 x HF8: [(1~{S},2~{R},3~{S},4~{S},5~{R},6~{S})-2-(hydroxymethyl)-3,4,5,6-tetrakis(oxidanyl)cyclohexyl] hydrogen sulfate(Covalent)
HF8.15: 13 residues within 4Å:- Chain A: W.16, D.61, D.62, Y.103, C.111, A.112, K.137, D.139, C.141, E.172, Y.176, R.196, D.200
13 PLIP interactions:13 interactions with chain A- Hydrophobic interactions: A:W.16, A:D.139
- Hydrogen bonds: A:D.62, A:D.62, A:A.112, A:K.137, A:K.137, A:R.196, A:R.196
- Water bridges: A:Y.176, A:D.200, A:D.200, A:D.235
HF8.29: 13 residues within 4Å:- Chain B: W.16, D.61, D.62, Y.103, C.111, A.112, K.137, D.139, C.141, E.172, Y.176, R.196, D.200
12 PLIP interactions:12 interactions with chain B- Hydrophobic interactions: B:W.16, B:D.139
- Hydrogen bonds: B:D.62, B:D.62, B:A.112, B:K.137, B:K.137, B:R.196, B:R.196, B:D.200
- Water bridges: B:D.200, B:D.235
- 18 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
EDO.16: 3 residues within 4Å:- Chain A: A.53, I.286, Q.290
Ligand excluded by PLIPEDO.17: 4 residues within 4Å:- Chain A: G.240, N.241, F.242, H.271
Ligand excluded by PLIPEDO.18: 3 residues within 4Å:- Chain A: Q.88, N.91, Y.92
Ligand excluded by PLIPEDO.19: 6 residues within 4Å:- Chain A: C.143, D.144, S.145, L.146, L.149, Y.176
Ligand excluded by PLIPEDO.20: 6 residues within 4Å:- Chain A: L.5, A.6, T.8, T.10, Y.57, V.168
Ligand excluded by PLIPEDO.21: 3 residues within 4Å:- Chain A: Y.176, P.179
- Ligands: EDO.22
Ligand excluded by PLIPEDO.22: 4 residues within 4Å:- Chain A: L.175, F.198, A.199
- Ligands: EDO.21
Ligand excluded by PLIPEDO.23: 3 residues within 4Å:- Chain A: E.43, Y.92, K.96
Ligand excluded by PLIPEDO.24: 6 residues within 4Å:- Chain A: L.1, S.157, L.158, Q.190, Y.191
- Ligands: NAG-NAG-BMA.1
Ligand excluded by PLIPEDO.30: 4 residues within 4Å:- Chain B: A.53, G.54, I.286, Q.290
Ligand excluded by PLIPEDO.31: 3 residues within 4Å:- Chain B: R.87, W.131
- Ligands: EDO.34
Ligand excluded by PLIPEDO.32: 6 residues within 4Å:- Chain B: W.246, A.278, L.279, D.282, L.357, P.358
Ligand excluded by PLIPEDO.33: 2 residues within 4Å:- Chain B: S.370, R.371
Ligand excluded by PLIPEDO.34: 6 residues within 4Å:- Chain B: A.77, G.85, I.86, R.87, W.131
- Ligands: EDO.31
Ligand excluded by PLIPEDO.35: 6 residues within 4Å:- Chain B: F.198, A.199, D.200, I.201, S.207, S.210
Ligand excluded by PLIPEDO.36: 6 residues within 4Å:- Chain B: T.8, P.9, T.10, M.11, G.54, Q.290
Ligand excluded by PLIPEDO.37: 1 residues within 4Å:- Chain B: R.270
Ligand excluded by PLIPEDO.38: 1 residues within 4Å:- Chain B: D.52
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Artola, M. et al., Alpha-d-Gal-cyclophellitol cyclosulfamidate is a Michaelis complex analog that stabilizes therapeutic lysosomal alpha-galactosidase A in Fabry disease. Chem Sci (2019)
- Release Date
- 2019-10-09
- Peptides
- Alpha-galactosidase A: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
B
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.07 Å
- Oligo State
- homo-dimer
- Ligands
- 3 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 2 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 1 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 2 x PEG: DI(HYDROXYETHYL)ETHER(Non-functional Binders)
- 4 x ACT: ACETATE ION(Non-functional Binders)
- 6 x SO4: SULFATE ION(Non-functional Binders)
- 2 x HF8: [(1~{S},2~{R},3~{S},4~{S},5~{R},6~{S})-2-(hydroxymethyl)-3,4,5,6-tetrakis(oxidanyl)cyclohexyl] hydrogen sulfate(Covalent)
- 18 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Artola, M. et al., Alpha-d-Gal-cyclophellitol cyclosulfamidate is a Michaelis complex analog that stabilizes therapeutic lysosomal alpha-galactosidase A in Fabry disease. Chem Sci (2019)
- Release Date
- 2019-10-09
- Peptides
- Alpha-galactosidase A: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
B